Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 20,596 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Terminated Phase 2 Interventional Results available

A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma

NCT01378871
View directory record Official record
Conditions
Adult T Cell Leukemia, Adult T Cell Lymphoma
Interventions
IMTOX-25
Drug
Lead sponsor
Amit Verma
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 17, 2026, 10:05 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

NCT03257644
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib phosphate cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Hoover, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 17, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

NCT00467844
View directory record Official record
Conditions
Cachexia
Interventions
GTx-024, Placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
Not listed
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
50
States / cities
Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 17, 2026, 10:05 PM EDT
Withdrawn Phase 2 Interventional

Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)

NCT01843998
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma (CTCL)
Interventions
Sirolimus 0.1% Ointment
Drug
Lead sponsor
Stefan Schieke MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 17, 2026, 10:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

NCT04192487
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea, Human Immunodeficiency Virus
Interventions
Crofelemer delayed-release tablets 125mg
Drug
Lead sponsor
Napo Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Tustin, California • Stratford, Connecticut • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 17, 2026, 10:05 PM EDT
Completed No phase listed Observational

Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS

NCT00232193
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
Providence Multiple Sclerosis Center
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 17, 2026, 10:05 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Biological Sample Collection for Research and Biobanking

NCT04270604
View directory record Official record
Conditions
Parkinson Disease, Diabetes Mellitus, Type 1, Macular Degeneration, ALS, Cancer, Alzheimer Disease, Huntington Disease
Interventions
Biological sample collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
1 Month to 100 Years
Enrollment
1,279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 17, 2026, 10:05 PM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 17, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

NCT00883558
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 17, 2026, 10:05 PM EDT
Completed Not applicable Interventional

Promoting Physical Activity for Persons With Multiple Sclerosis

NCT00513448
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Group wellness intervention, Individualized physical rehabilitation
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 8, 2007 · Synced Oct 17, 2026, 10:05 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Video-Based Delivery of HIV Test Information for Spanish-Speaking Latinos

NCT01452555
View directory record Official record
Conditions
HIV, AIDS
Interventions
Video or In-Person Presentation
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 17, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders

NCT01050855
View directory record Official record
Conditions
Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies
Interventions
Reduced-Intensity Conditioning
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 25 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 17, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine

NCT00002333
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
41
States / cities
Harbor City, California • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 10:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

NCT00624338
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Atacicept 75 mg, Atacicept 150 mg, Placebo Comparator
Drug · Other
Lead sponsor
EMD Serono
Industry
Eligibility
16 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 17, 2026, 10:05 PM EDT
Withdrawn Phase 2 Interventional

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

NCT03328936
View directory record Official record
Conditions
Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Melphalan Hydrochloride, Pharmacological Study
Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 17, 2026, 10:05 PM EDT
Terminated Not applicable Interventional Results available

Smart Glucose Meter Project

NCT01341587
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Telcare Blood Glucose Meter (BGM)
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 17, 2026, 10:05 PM EDT
Completed No phase listed Observational

Measurements of Resting Energy Expenditure in Patients With or at Risk of Developing Graft Versus Host Disease

NCT00600314
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
7 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 17, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

BI 671800 in Asthmatic Patients on Inhaled Corticosteroids

NCT01103349
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Placebo, Montelukast
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 17, 2026, 10:05 PM EDT
Recruiting Phase 2 Interventional

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

NCT04232085
View directory record Official record
Conditions
Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure, Short Telomere Length, Fanconi Anemia, Non Fanconi DNA-DSB Repair Disorder, Hoyeraal-Hreidarsson Syndrome, Dyskeratosis Congenita, Telomere Biology Disorder, Short Telomere Syndrome
Interventions
Alemtuzumab, Fludarabine, Melphalan, Low Dose Total Body Irradiation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
4 Months to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 17, 2026, 10:05 PM EDT
Completed Not applicable Interventional

A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS

NCT02490943
View directory record Official record
Conditions
MS (Multiple Sclerosis), Erythema
Interventions
Warm Compress Before Injection, Cold Compress After Injection
Other
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 17, 2026, 10:05 PM EDT
Not yet recruiting Not applicable Interventional

Improving TelePrEP Initiation and Retention Outcomes in the US: The MISTR+ Study

NCT07821671
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
No Marginal Cost Interventions, Low-Marginal Cost Interventions, Standard of Care
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
223,165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 17, 2026, 10:05 PM EDT
Recruiting Phase 1 Interventional

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

NCT07477587
View directory record Official record
Conditions
Multiple Myeloma (MM)
Interventions
HLX15-SC-Rd, US-DARZALEX FASPRO®-Rd
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Springdale, Arkansas • Jacksonville, Florida • Margate, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 10:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide, Lenalidomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
44
States / cities
Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 17, 2026, 10:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pancreas Volume in Preclinical Type 1 Diabetes

NCT02234947
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MRI, US, and blood samples
Procedure
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 45 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 17, 2026, 10:05 PM EDT